2002
DOI: 10.1096/fj.02-0030fje
|View full text |Cite
|
Sign up to set email alerts
|

Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin

Abstract: We previously have found that advanced glycation end products (AGE), senescent macroproteins formed at an accelerated rate in diabetes, arise in vivo not only from glucose but also from reducing sugars. Furthermore, we recently have shown that glyceraldehyde- and glycolaldehyde-derived AGE (glycer- and glycol-AGE) are mainly involved in loss of pericytes, the earliest histopathological hallmark of diabetic retinopathy. However, the effects of these AGE proteins on angiogenesis, another vascular derangement in … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

6
174
0
1

Year Published

2005
2005
2021
2021

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 243 publications
(181 citation statements)
references
References 44 publications
6
174
0
1
Order By: Relevance
“…The beneficial effects of statin treatment in the diabetic retina were found to correlate with their ability to suppress redox-dependent activation of STAT3 (Al-Shabrawey et al, submitted). Statins have also been shown to inhibit angiotensin-induced activation of STAT3 in vitro (Horiuchi et al, 2003) and to prevent VEGF expression induced by advanced glycation end-products (Okamoto et al, 2002;Scalia and Stalker, 2002;Weis et al, 2002). These and other important therapeutic effects of statins are due not only to their lipid lowering ability, but also to their potent antioxidant and anti-inflammatory properties (Sowers, 2003).…”
Section: 74mentioning
confidence: 99%
“…The beneficial effects of statin treatment in the diabetic retina were found to correlate with their ability to suppress redox-dependent activation of STAT3 (Al-Shabrawey et al, submitted). Statins have also been shown to inhibit angiotensin-induced activation of STAT3 in vitro (Horiuchi et al, 2003) and to prevent VEGF expression induced by advanced glycation end-products (Okamoto et al, 2002;Scalia and Stalker, 2002;Weis et al, 2002). These and other important therapeutic effects of statins are due not only to their lipid lowering ability, but also to their potent antioxidant and anti-inflammatory properties (Sowers, 2003).…”
Section: 74mentioning
confidence: 99%
“…Other observations in diabetic animals are compatible with a pathogenetic role for AGEs in microvascular disease. Similarly AGEs alone are given to achieve plasma concentrations equivalent to those seen in diabetic animals [47]. After 5 months, the renal AGE content in AGE-treated rats was 50% above that in controls, while the plasma concentration was 2.8 times greater than that of controls.…”
Section: Accumulation Of Agesmentioning
confidence: 99%
“…Interestingly, acetylsalicylic acid -a drug widely use in patients suffering from atherosclerotic disease -and pentoxifyllin -a drug used in patients with peripheral artery disease -also inhibit non-enzymatic glycation [23]. Finally, the β-HMG CoA reductase inhibitor cerivastatin has been shown to inhibit AGE formation [24].…”
Section: Advanced Glycation End Products (Age)mentioning
confidence: 99%